Literature DB >> 19200837

Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma.

Giuseppina Cantarella1, Matthias Liniger, Armando Zuniga, John T Schiller, Martin Billeter, Hussein Y Naim, Reinhard Glueck.   

Abstract

Cervical cancer is mainly associated with HPV genotype 16 infection. Recombinant measles virus (rMV) expressing HPV genotype 16 L1 capsid protein was generated by construction of an antigenomic plasmid, followed by rescue using the human "helper" cell line 293-3-46. In cell cultures the recombinant MV-L1 virus replicated practically as efficiently as the standard attenuated MV established as commercial vaccine, devoid of the transgene. The high genetic stability of MVb2-L1 was confirmed by 10 serial viral transfers in cell culture. In transgenic mice expressing the MV receptor CD46 the recombinant induced strong humoral immune responses against both MV and HPV; the antibodies against L1 exhibited mainly neutralizing capacity. Our data suggest that MV is a promising vehicle for development of inexpensive and efficient vaccines protecting from HPV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200837      PMCID: PMC3487399          DOI: 10.1016/j.vaccine.2009.01.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector.

Authors:  Frédéric Tangy; Hussein Y Naim
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

3.  A recombinant measles virus expressing biologically active human interleukin-12.

Authors:  M Singh; M A Billeter
Journal:  J Gen Virol       Date:  1999-01       Impact factor: 3.891

Review 4.  Molecular diagnosis of human papillomavirus (HPV) infections.

Authors:  Anco Molijn; Berhard Kleter; Wim Quint; Leen-Jan van Doorn
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

Review 5.  Prospects and prejudices of human papillomavirus vaccines in India.

Authors:  Bhudev C Das; Showket Hussain; Vilas Nasare; Mausumi Bharadwaj
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

6.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

7.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  Attenuated measles virus as a vaccine vector.

Authors:  Armando Zuniga; Zili Wang; Matthias Liniger; Lars Hangartner; Michael Caballero; Jovan Pavlovic; Peter Wild; Jean Francois Viret; Reinhard Glueck; Martin A Billeter; Hussein Y Naim
Journal:  Vaccine       Date:  2007-02-02       Impact factor: 3.641

10.  Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.

Authors:  Matthias Liniger; Armando Zuniga; Azaibi Tamin; Teldja N Azzouz-Morin; Marlyse Knuchel; Rene R Marty; Marian Wiegand; Sara Weibel; David Kelvin; Paul A Rota; Hussein Y Naim
Journal:  Vaccine       Date:  2008-02-22       Impact factor: 3.641

View more
  24 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

Review 2.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

3.  HPV vaccines: Global perspectives.

Authors:  Gaurav Gupta; Reinhard Glueck; Pankaj R Patel
Journal:  Hum Vaccin Immunother       Date:  2017-03-31       Impact factor: 3.452

Review 4.  Reducing HPV-associated cancer globally.

Authors:  Douglas R Lowy; John T Schiller
Journal:  Cancer Prev Res (Phila)       Date:  2012-01

Review 5.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 6.  New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Authors:  Elizabeth D Gersch; Lutz Gissmann; Robert L Garcea
Journal:  Antivir Ther       Date:  2011-11-07

7.  Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.

Authors:  Jorge Reyes-del Valle; Cynthia de la Fuente; Mallory A Turner; Christoph Springfeld; Swapna Apte-Sengupta; Marie E Frenzke; Amelie Forest; Jillian Whidby; Joseph Marcotrigiano; Charles M Rice; Roberto Cattaneo
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

8.  An immune competent mouse model for the characterization of recombinant measles vaccines.

Authors:  René R Marty; Marlyse C Knuchel; Teldja Neige Azzouz Morin; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 9.  Measles virus.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 10.  A review of clinical trials of human papillomavirus prophylactic vaccines.

Authors:  John T Schiller; Xavier Castellsagué; Suzanne M Garland
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.